Skip to content

Goodwill at other companies

Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$145.93M-3.2%
Viatris logo
ViatrisVTRS
$6.69B+3.6%
PTH
Pelthos Therapeutics Inc.PTHS
$24.68M
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$24.16M-8.9%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$4.7M0.0%
Opko Health logo
Opko HealthOPK
$482.27M+1.2%

Other financials

Income statement

See full
Revenue$8.6M+72.1%
Gross profit$4.2M+15.1%
Operating income-$32.2M-15.3%
Net income-$45.7M-75.0%
EPS (diluted)-$6.28-178%

Balance sheet

See full
Cash & equivalents$3.4M-42.2%
Total debt$95.4M+130%
Total equity-$249.2M-17.8%
Total assets$293.6M+272%

Cash flow

See full
Operating cash flow-$1.1M-118%
CapEx$33.3K
Free cash flow$920.8K-63.7%

Valuation

See full
Market cap$54.86M+88.4%
Enterprise value$146.86M+120%
P/S1.6×+1.0×

Profitability

See full
Gross margin59.7%-12.3pp
Operating margin-1,034.4%-1,313pp
Net margin-1,162.4%-1,359pp
FCF margin12.2%

Returns & leverage

See full
Return on equity170.9%
Debt / equity0.3×
Current ratio0.1×0.0×

Where this comes from

Reported directly by Scilex Holding Company in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: Scilex Holding Company’s 10-Q, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scilex Holding Company's goodwill.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scilex Holding Company's goodwill?
Scilex Holding Company (SCLX) reported goodwill of $13.48M in Q1 2026.
How has Scilex Holding Company's goodwill changed year-over-year?
Scilex Holding Company's goodwill decreased by 0.0% year-over-year, from $13.48M to $13.48M.
What is the long-term trend for Scilex Holding Company's goodwill?
Over 4 years (2021 to 2025), Scilex Holding Company's goodwill has grown at a 0.0% compound annual growth rate (CAGR), from $13.48M to $13.48M.
What does goodwill mean?
The excess of acquisition cost over the fair value of net identifiable assets acquired — representing brand value, customer relationships, and synergies from past M&A.